Adverse events after Japanese encephalitis vaccination: review of post-marketing surveillance data from Japan and the United States. The VAERS Working Group.
about
Vaccines for preventing Japanese encephalitisJapanese encephalitis: the virus and vaccinesJE Nakayama/JE SA14-14-2 virus structural region intertypic viruses: Biological properties in the mouse model of neuroinvasive diseaseCrystal Structure of the Japanese Encephalitis Virus Envelope ProteinGuillain-barré syndrome following influenza vaccination: causal or coincidental?DnaJ homolog Hdj2 facilitates Japanese encephalitis virus replicationActive immunization in the United States: developments over the past decade.Japanese Encephalitis VaccinesThe effect of insecticide-treated mosquito nets (ITMNs) on Japanese encephalitis virus seroconversion in pigs and humans.Japanese encephalitis vaccine for travelers: exploring the limits of risk.Methods of ensuring vaccine safety.Vital role of medical examiners and coroners in organ transplantation.New adjuvants: EU regulatory developments.Immunization issues in pediatric travelers.Expert opinion on vaccination of travelers against Japanese encephalitis.A tripeptide (NSK) inhibits Japanese encephalitis virus infection in vitro and in vivo.The practice of travel medicine: guidelines by the Infectious Diseases Society of America.Japanese encephalitis vaccines: Immunogenicity, protective efficacy, effectiveness, and impact on the burden of disease.Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2009-2012.Vaccination in solid organ transplantation.Anaphylaxis to Japanese encephalitis vaccine.Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12-18 months: randomized, controlled phase 3 immunogenicity and safety trial.Immunogenicity and safety of inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children.
P2860
Q24243819-6C89D19C-9999-44D1-9ED4-24EE1A52A605Q27010434-3ED29F96-DE5B-4986-9055-4406C02BDC29Q27485478-C822C760-1816-4ECC-8138-F96CC0DB595FQ27676100-A55D7288-4592-445A-A4E4-296BA2DAA823Q30403959-F810ABC4-22FE-4E47-B419-0FD75BD91AAFQ31038877-C5FDCE52-A691-43CE-B9F7-AE3CB1B6B6ADQ33975799-76B72A6C-0004-4E92-868E-979BE1C1599DQ34466587-AC9486C8-8CA6-4F22-9A82-D4DFF6124BF3Q34592258-C18A240F-4752-4A68-B7C7-D63889751039Q34711618-9A065339-1A9D-4941-A10D-3D18159BAEB4Q35193420-3A7BA6F7-F2BB-4CA4-B36E-935931009A9BQ35671634-225C74BD-0AA2-4572-A858-A9D67AE6A0FAQ36968305-795DA936-A7D6-4C3C-AA4C-F913DD4C04BDQ37194794-0BE396A7-C6D1-4939-8B50-1DCE4C177780Q37524448-6D702197-0D3F-4990-9358-FE46F7CF525DQ39051535-547A9898-F78D-4E53-8B59-132B8FDD9C5EQ39067681-066CA0E3-39C5-4688-9400-3DC03956352BQ39181962-AC09D436-7466-45BC-8D53-1B2BB2C7C2FDQ41701215-3FEAA99E-07C5-4EF3-B8E4-94ADDAB4314EQ42272271-E8B1881E-A7E8-4245-AB94-ADCE281A608FQ43033547-33BDB7F2-041A-4E45-A5ED-1DCB34E73E64Q47403621-A77B1852-B024-4129-9AA0-7C1753DDFBCAQ47567267-338DA9F5-DB7A-4950-A14B-867E71D3E429
P2860
Adverse events after Japanese encephalitis vaccination: review of post-marketing surveillance data from Japan and the United States. The VAERS Working Group.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Adverse events after Japanese ...... ates. The VAERS Working Group.
@ast
Adverse events after Japanese ...... ates. The VAERS Working Group.
@en
type
label
Adverse events after Japanese ...... ates. The VAERS Working Group.
@ast
Adverse events after Japanese ...... ates. The VAERS Working Group.
@en
prefLabel
Adverse events after Japanese ...... ates. The VAERS Working Group.
@ast
Adverse events after Japanese ...... ates. The VAERS Working Group.
@en
P2093
P1433
P1476
Adverse events after Japanese ...... ates. The VAERS Working Group.
@en
P2093
P304
P356
10.1016/S0264-410X(00)00111-0
P407
P577
2000-07-01T00:00:00Z